The Correlation of Remission Induction Therapy with Plasma Vascular Endothelial Growth Factor Level in Acute Myeloid Leukemia Patients
Iraqi Postgraduate Medical Journal,
2021, Volume 20, Issue 1, Pages 27-32
Angiogenesis seems to be important for leukemogenesis and susceptibility to intensive chemotherapy, and high levels of vascular endothelial growth factor (VEGF) is detected in acute myeloid leukemia (AML) patients
AIM OF THE STUDY:
To assess the correlation of plasma VEGF level with the response to remission induction therapy in adult AML PATIENTS.
PATIENTS AND METHODS:
An analytical cross-sectional study performed on thirty adult patients with newly diagnosed AML. Plasma VEGF level measured by ELISA in all patients twice, before and after chemotherapy.
The VEGF level was significantly higher in AML patients, at presentation, than control group with median level of 88.13 pg/mL and 49.26 pg/mL, respectively (P=0.002). The median VEGF level decreased after chemotherapy in patients who achieved complete remission although not statistically significant (P=0.071). Whereas the level increased significantly after treatment in patients who failed to response to induction therapy, from 66.27 pg/mL to 165.37 pg/mL (P= 0.025).
Plasma VEGF level was high in adult AML patients at presentation and increases significantly after induction therapy in AML patients who responded poorly to treatment. However, in patients who achieved complete remission the level normalize after therapy, although statistically insignificant.
- Brunner AM, Graubert TA. Pathobioloby of acute myeloid leukemia, In: Hoffman R, Benz EJ, Silberstein LE, et al. editors. Hematology Basic Principles and Practice. 7th ed. Philadelphia: Elsevier, Inc. 2018: 913-16.
- Petrovic, N. Targeting Angiogenesis in Cancer Treatments: Where do we stand? Journal of Pharmacy & Pharmaceutical Sciences. 2016; 19:226-38.
- Lee SH, Jeong D, Han YS, Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Annual Surgical Treat and Research. 2015;89:1-8.
- Salajegheh A. Vascular Endothelial Growth Factor (VEGF). In: Angiogenesis in Health, Disease and Malignancy. Springer, Cham. 2016: 363-74.
- List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Experimental Hematology 2004; 32: 526-35.
- Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16:1302-10.
- Kalra M, Dinand V, Choudhary S, Sachdeva A, et al. Serum vascular endothelial growth factor-A levels during induction therapy in children with acute lymphoblastic leukemia. Indian Pediatrics 2013; 50: 659-62.
- Najafabadi MM, K. Shamsasenjan K, Akbarzadehalaleh P. Angiogenesis Status in Patients with Acute Myeloid Leukemia: From Diagnosis to Post-hematopoietic Stem Cell Transplantation. International Journal of Organ Transplant Medicine 2017; 8: 57-67.
- Döhner H, Estey E, Grimwade D, Amadori S, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424.
10. Almohsen FS, Al-Mudallal SS. Relationship between the expression of CD34, CD123 and myeloperoxidase markers by flow cytometry and response to induction therapy in acute myeloid leukemia. Iraqi Journal of Medical Sciences 2014; 12: 161-67.
11. Dhahir EK, Al-Mudallel SS, Dhahi MA. The frequency of FLT3 mutation in fifty five Iraqi adult patients with acute myeloid leukemia. Iraqi Journal of Medical Sciences 2012; 10: 140-47.
12. Al- Maaroof ZW, Yahya DhJ, Hassoon AF. Evaluation of leukemia inhibitory factor, interleukin 6 and leptin in acute and chronic myeloid leukemia in Babylon Province. Medical Journal of Babylon 2016; 2:513-21.
13. UdayaKumar AM, Pathare AV, Al-Kindi S, Khan H, Rehmen JU, Zia F, et al. Cytogenetic, morphological, and immunophenotypic patterns in Omani patients with de novo acute myeloid leukemia. Cancer Genetics and Cytogenetics 2007; 177: 89-94.
14. Aguayo A, Kantarijian HM, Estey EH, Giles FJ, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95:1923-30.
15. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89:1870-75.
- 16. Lee CY, Tien HF, Hu CY, Chou WC, Lin LI. Marrow angiogenesis- associated factors as prognostic biomarkers in patients with acute myeloid leukemia. British Journal of Cancer 2007; 97: 877-82.
- 17. Ismail MA, Eisaa DS, Heiba NM. Celullar vascular endothelial growth factor and serum angiogenin in acute myeloid leukemia: clinical and prognostic significance. Egyptian Journal of Haematology 2013; 38:41-46.
18. Brunner B, Gunsilius E, Schumacher P, Zwierzina H, et al. Blood levels of angiogenin and vascular endothleial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. Journal of Hematotherapy & Stem Cell Research 2002; 11:119-25.
19. Zhang J, Ma D, Ye J, Zang S, Lu F, et al. Prognostic impact of d-like ligand 4 and notch 1 in acute myeloid leukemia. Oncology Reports 2012;28:1503-11.
20. Karp JE, Gogo I, Pili R, Gocke CD, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research. 2004;10: 3577-85.
- Article View: 96
- PDF Download: 72